Substance P vs ANP (Atrial Natriuretic Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →Side-by-Side Comparison
| Aspect | Substance P | ANP (Atrial Natriuretic Peptide) |
|---|---|---|
| Mechanism | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. |
| Typical Dosage | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. |
| Administration | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. |
| Side Effects | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. |
| Best For |